New LDL-lowering drug is under FDA review
03/15/19 • 6 min
This week in MDedge Cardiocast: A novel drug lowers LDL in on top of maximums statins, invasive cardiology is a top money maker for hospitals, a meta-analysis parses the heart and kidney benefits of new diabetes drugs, and the AHA warns that heart-harming toxins may hurt hookah smokers.
This week in MDedge Cardiocast: A novel drug lowers LDL in on top of maximums statins, invasive cardiology is a top money maker for hospitals, a meta-analysis parses the heart and kidney benefits of new diabetes drugs, and the AHA warns that heart-harming toxins may hurt hookah smokers.
Previous Episode
Forget what you learned about infective endocarditis
This week in MDedge Cardiocast: Infective endocarditis isn’t what it used to be, there’s a new, lower goal for Americans’ dietary intake of sodium, a drug to treat myeloma also raises heart failure risk, and Big Pharma says it can’t drop drug list prices alone.
Next Episode
Top News from ACC 19
Cardiovascular prevention guidelines downgrade aspirin, high coronary artery calcium scores carry greater risks, an Apple Watch algorithm predicts AFib, and TAVR overtakes surgery in "historic" trials.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/mdedge-cardiocast-389406/new-ldl-lowering-drug-is-under-fda-review-55206544"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to new ldl-lowering drug is under fda review on goodpods" style="width: 225px" /> </a>
Copy